Myoglobin Market Outlook:
Myoglobin Market size was valued at USD 108.2 million in 2025 and is projected to reach USD 164.7 million by the end of 2035, rising at a CAGR of 4.3% during the forecast period, i.e., 2026-2035. In 2026, the industry size of myoglobin is assessed at USD 112.8 million.
The patient population driving the demand for myoglobin testing is defined by the high prevalence of cardiovascular disorders. Cardiovascular diseases account for the highest numbers of fatalities worldwide, with the World Health Organization report in 2025 estimating that they claim 17.9 million lives annually. These high numbers of patients require urgent diagnostic tools in emergency and clinical care environments, supporting demand for cardiac biomarkers. The myoglobin immunoassay supply. chain is elaborate and globalized, with international trade of specialized raw materials.
Investment in research, development, and deployment (RDD) for the sector goes mainly into improving assay performance and integration into automated laboratory systems. Cardiovascular research funding by both public and private sources underlies biomarker discovery and validation. For example, the AHA Journal in July 2025 approximated that in 2024, the AHA funded over 1800 active research awards, which covered almost USD 500 million, part of which sponsors the creation of better diagnostic methods. Deployment is strongly driven by health policy and reimbursement frameworks.
